Please login to the form below

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi and Regeneron are also working on bispecific antibody immunotherapies, including two lead candidate targeting BCMA/CD3 and MUC/CD3, respectively.

Latest news

Regeneron reveals first data for bispecific antibody in multiple myeloma

The antibody targets BCMA, a protein that is typically over-expressed on multiple myeloma cells, by binding to it and the CD3 receptor on T-cells, bringing them together and activating ... CD3 targeting bispecific antibody.
Provention Bio wins PRIME designation for type 1 diabetes prevention drug

Teplizumab works by binding to the pro-inflammatory T cell co-receptor CD3, which in turn prevents them from activating the T cells that attack and kill the pancreas’ beta cells.
Tiziana joins type 1 diabetes prevention field

Teplizumab is a mouse derived anti-CD3 mAb, and is administered intravenously. ... Now Tiziana is looking to rival Provention with the development of its own anti-CD3 mAB foralumab, which it says is the only entirely human anti-CD3 mAb.
Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in DLBCL and follicular lymphoma, and moving the ADC into earlier lines of therapy.
Type 1 diabetes prevention promise sends Provention Bio soaring

Teplizumab works by binding to the pro-inflammatory T cell co-receptor CD3, which in turn prevents them from activating the T cells that attack and kill the pancreas’ beta cells.

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Taking a lean and careful approach

Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
Deal Watch June 2016

Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
Pharma deals during December 2014

platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
Pharma deals during February 2014

CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward: ...
Can eLearning improve patient recruitment and retention?: Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
How Far Do You Want To Go?: Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...